Cargando…
Expression of CD44 and the survival in glioma: a meta-analysis
Background: Higher tumor expression of CD44, a marker of cancer stem cells (CSCs), is associated with poor overall survival (OS) in various cancers. However, the association between CD44 and poor OS remains inconsistent in glioma. We aimed to evaluate the potential predictive role of CD44 for progno...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160241/ https://www.ncbi.nlm.nih.gov/pubmed/32232385 http://dx.doi.org/10.1042/BSR20200520 |
_version_ | 1783522723153051648 |
---|---|
author | Wu, Gang Song, Xinghui Liu, Jun Li, Shize Gao, Weiqin Qiu, Mingxing Yang, Changjin Ma, Yiming Chen, Yuhong |
author_facet | Wu, Gang Song, Xinghui Liu, Jun Li, Shize Gao, Weiqin Qiu, Mingxing Yang, Changjin Ma, Yiming Chen, Yuhong |
author_sort | Wu, Gang |
collection | PubMed |
description | Background: Higher tumor expression of CD44, a marker of cancer stem cells (CSCs), is associated with poor overall survival (OS) in various cancers. However, the association between CD44 and poor OS remains inconsistent in glioma. We aimed to evaluate the potential predictive role of CD44 for prognosis of glioma patients in a meta-analysis. Methods: Observational studies comparing OS of glioma patients according to the level of CD44 were identified through searching PubMed, Embase, and Cochrane’s Library databases. Meta-analyses were performed with a random- or fixed-effect model according to the heterogeneity. Subgroup analyses were performed to evaluate the influences of study characteristics. Results: Eleven retrospective cohort studies were included. Results showed that increased CD44 expression in tumor predicted poor OS in glioma patients (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.02–1.97, P=0.04). Subgroup analyses showed that higher tumor CD44 expression significantly predicted poor OS in patients with World Health Organization (WHO) stages II–III glioma (HR: 2.99, 95% CI: 1.53–5.89, P=0.002), but not in patients with glioblastoma (HR: 1.26, 95% CI: 0.76–2.08, P=0.47; P for subgroup difference = 0.03). Results were not statistically different between subgroups according to patient ethnicity, sample size, CD44 detection method, CD44 cutoff, HR estimation, univariate or multivariate analysis, or median follow-up durations (P-values for subgroup difference all >0.10). Conclusion: Higher tumor expression of CD44 may predict poor survival in patients with glioma, particularly in those with WHO stage II–III glioma. |
format | Online Article Text |
id | pubmed-7160241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71602412020-04-21 Expression of CD44 and the survival in glioma: a meta-analysis Wu, Gang Song, Xinghui Liu, Jun Li, Shize Gao, Weiqin Qiu, Mingxing Yang, Changjin Ma, Yiming Chen, Yuhong Biosci Rep Cancer Background: Higher tumor expression of CD44, a marker of cancer stem cells (CSCs), is associated with poor overall survival (OS) in various cancers. However, the association between CD44 and poor OS remains inconsistent in glioma. We aimed to evaluate the potential predictive role of CD44 for prognosis of glioma patients in a meta-analysis. Methods: Observational studies comparing OS of glioma patients according to the level of CD44 were identified through searching PubMed, Embase, and Cochrane’s Library databases. Meta-analyses were performed with a random- or fixed-effect model according to the heterogeneity. Subgroup analyses were performed to evaluate the influences of study characteristics. Results: Eleven retrospective cohort studies were included. Results showed that increased CD44 expression in tumor predicted poor OS in glioma patients (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.02–1.97, P=0.04). Subgroup analyses showed that higher tumor CD44 expression significantly predicted poor OS in patients with World Health Organization (WHO) stages II–III glioma (HR: 2.99, 95% CI: 1.53–5.89, P=0.002), but not in patients with glioblastoma (HR: 1.26, 95% CI: 0.76–2.08, P=0.47; P for subgroup difference = 0.03). Results were not statistically different between subgroups according to patient ethnicity, sample size, CD44 detection method, CD44 cutoff, HR estimation, univariate or multivariate analysis, or median follow-up durations (P-values for subgroup difference all >0.10). Conclusion: Higher tumor expression of CD44 may predict poor survival in patients with glioma, particularly in those with WHO stage II–III glioma. Portland Press Ltd. 2020-04-15 /pmc/articles/PMC7160241/ /pubmed/32232385 http://dx.doi.org/10.1042/BSR20200520 Text en © 2020 The Author(s). https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). |
spellingShingle | Cancer Wu, Gang Song, Xinghui Liu, Jun Li, Shize Gao, Weiqin Qiu, Mingxing Yang, Changjin Ma, Yiming Chen, Yuhong Expression of CD44 and the survival in glioma: a meta-analysis |
title | Expression of CD44 and the survival in glioma: a meta-analysis |
title_full | Expression of CD44 and the survival in glioma: a meta-analysis |
title_fullStr | Expression of CD44 and the survival in glioma: a meta-analysis |
title_full_unstemmed | Expression of CD44 and the survival in glioma: a meta-analysis |
title_short | Expression of CD44 and the survival in glioma: a meta-analysis |
title_sort | expression of cd44 and the survival in glioma: a meta-analysis |
topic | Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160241/ https://www.ncbi.nlm.nih.gov/pubmed/32232385 http://dx.doi.org/10.1042/BSR20200520 |
work_keys_str_mv | AT wugang expressionofcd44andthesurvivalingliomaametaanalysis AT songxinghui expressionofcd44andthesurvivalingliomaametaanalysis AT liujun expressionofcd44andthesurvivalingliomaametaanalysis AT lishize expressionofcd44andthesurvivalingliomaametaanalysis AT gaoweiqin expressionofcd44andthesurvivalingliomaametaanalysis AT qiumingxing expressionofcd44andthesurvivalingliomaametaanalysis AT yangchangjin expressionofcd44andthesurvivalingliomaametaanalysis AT mayiming expressionofcd44andthesurvivalingliomaametaanalysis AT chenyuhong expressionofcd44andthesurvivalingliomaametaanalysis |